Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Letrozole

Letrozole Am J Cancer 2002; 1 (5): 351-371 ADIS DRUG EVALUATION 1175-6357/02/0005-0351/$25.00/0 © Adis International Limited. All rights reserved. An Updated Review of its Use in Postmenopausal Women with Advanced Breast Cancer Gillian M. Keating and Blair Jarvis Adis International Inc., Langhorne, Pennsylvania, USA Various sections of the manuscript reviewed by: S. Chan, Department of Clinical Oncology, City Hospital, Nottingham, United Kingdom; M. de Lena, Operative Unit of Medical Oncology, Oncology Institute, Bari, Italy; J.M. Dixon, Breast Research Unit, Western General Hospital, Edinburgh, United Kingdom; W.J. Gradishar, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA; H.T. Mouridsen, Department of Oncology, The Finsen Center, Copenhagen, Denmark; S. Pyrhönen, Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland. Data Selection Sources: Medical literature published in any language since October 1998 on Letrozole, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘Letrozole’ or ‘CGS 20267’. EMBASE search terms were ‘Letrozole’ or ‘CGS 20267’. AdisBase search terms were ‘Letrozole’ or ‘CGS http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/letrozole-FY146g2Luj
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201050-00007
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2002; 1 (5): 351-371 ADIS DRUG EVALUATION 1175-6357/02/0005-0351/$25.00/0 © Adis International Limited. All rights reserved. An Updated Review of its Use in Postmenopausal Women with Advanced Breast Cancer Gillian M. Keating and Blair Jarvis Adis International Inc., Langhorne, Pennsylvania, USA Various sections of the manuscript reviewed by: S. Chan, Department of Clinical Oncology, City Hospital, Nottingham, United Kingdom; M. de Lena, Operative Unit of Medical Oncology, Oncology Institute, Bari, Italy; J.M. Dixon, Breast Research Unit, Western General Hospital, Edinburgh, United Kingdom; W.J. Gradishar, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA; H.T. Mouridsen, Department of Oncology, The Finsen Center, Copenhagen, Denmark; S. Pyrhönen, Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland. Data Selection Sources: Medical literature published in any language since October 1998 on Letrozole, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘Letrozole’ or ‘CGS 20267’. EMBASE search terms were ‘Letrozole’ or ‘CGS 20267’. AdisBase search terms were ‘Letrozole’ or ‘CGS

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References